Grey Wolf Therapeutics is an Oxford, UK-based clinical-stage biotechnology company using an antigen modulation platform to discover and develop therapies. Its lead clinical candidate, GRWD5769, is a potent and selective oral ERAP1 inhibitor designed to elicit a differentiated immune response against tumours. A second ERAP1 inhibitor, GRWD0715, is in preclinical development as a potential treatment for autoimmune disease, and the company is advancing an ERAP2 drug discovery program. Grey Wolf is also exploring therapeutic targeting of ERAP1-inhibitor–generated cancer antigens with MHC Class I directed therapies, including soluble T cell receptor and TCR mimic bispecifics. The company is led by CEO Peter Joyce and will use recent financing to broaden its Phase 1/2 trial across additional solid tumour types and to expand R&D into autoimmune indications. The financing increased the company’s reported total to $99M. Grey Wolf Therapeutics is an Oxford, UK-based biotechnology company developing a new immuno-oncology approach that creates novel cancer antigens by inhibiting ERAP1 or ERAP2. The company is developing a portfolio of potentially first-in-class small-molecule ERAP inhibitors. Its lead candidate, GRWD5769, is a potent and selective ERAP1 inhibitor that elicits a differentiated immune response and is entering the clinic in the first half of 2023. A second program targeting ERAP2 is advancing through discovery. The company intends to use new funding to support continued development of its immuno-oncology approaches and to advance GRWD5769 into a Phase 1/2 clinical trial. Grey Wolf is led by CEO Peter Joyce, Ph.D. Grey Wolf Therapeutics is a UK‑based drug discovery biotech focused on immuno‑oncology, developing small‑molecule modulators of endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2) to change the neoantigen repertoire and increase tumour visibility. Its lead program targets ERAP1 with the aim of broadening the effectiveness of approved immunotherapies without the complex personalization required for approaches such as neoantigen vaccines. The company works with the University of Oxford, University of Southampton and has a strategic partnership with Sygnature Discovery, which is also an investor. Grey Wolf was co‑founded by Peter Joyce and Tom McCarthy and comprises a team experienced in immuno‑oncology, antigen presentation and drug discovery. It completed a £10 million ($14 million) Series A financing to fund development of its immuno‑oncology programs. Management says the financing will support existing collaborations and the development of a clinical candidate against ERAP1 in the coming two to three years.

Total raised

$112M

Funding rounds

3

Latest round

Series B

Latest activity

May 2024